Summit soars after $2 billion investment from AstraZeneca for cancer therapies

Summit Therapeutics' NASDAQ:SMMT shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca LSE:AZN would invest $2 billion in the company to test cancer treatments together.UK-listed shares of AstraZeneca were up 1.6% to a two-month high after the Anglo-Swedish company an…